These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 9548597

  • 1. Apolipoprotein E2 (Arg136 --> Cys) mutation in the receptor binding domain of apoE is not associated with dominant type III hyperlipoproteinemia.
    März W, Hoffmann MM, Scharnagl H, Fisher E, Chen M, Nauck M, Feussner G, Wieland H.
    J Lipid Res; 1998 Mar; 39(3):658-69. PubMed ID: 9548597
    [Abstract] [Full Text] [Related]

  • 2. Apolipoprotein E2-Dunedin (228 Arg replaced by Cys): an apolipoprotein E2 variant with normal receptor-binding activity.
    Wardell MR, Rall SC, Brennan SO, Nye ER, George PM, Janus ED, Weisgraber KH.
    J Lipid Res; 1990 Mar; 31(3):535-43. PubMed ID: 2341812
    [Abstract] [Full Text] [Related]

  • 3. Variable heparan sulfate proteoglycan binding of apolipoprotein E variants may modulate the expression of type III hyperlipoproteinemia.
    Ji ZS, Fazio S, Mahley RW.
    J Biol Chem; 1994 May 06; 269(18):13421-8. PubMed ID: 8175773
    [Abstract] [Full Text] [Related]

  • 4. The functional characteristics of a human apolipoprotein E variant (cysteine at residue 142) may explain its association with dominant expression of type III hyperlipoproteinemia.
    Horie Y, Fazio S, Westerlund JR, Weisgraber KH, Rall SC.
    J Biol Chem; 1992 Jan 25; 267(3):1962-8. PubMed ID: 1730728
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Apolipoprotein E isoforms and rare mutations: parallel reduction in binding to cells and to heparin reflects severity of associated type III hyperlipoproteinemia.
    Mann WA, Meyer N, Weber W, Meyer S, Greten H, Beisiegel U.
    J Lipid Res; 1995 Mar 25; 36(3):517-25. PubMed ID: 7775863
    [Abstract] [Full Text] [Related]

  • 9. Molecular mechanisms of type III hyperlipoproteinemia: The contribution of the carboxy-terminal domain of ApoE can account for the dyslipidemia that is associated with the E2/E2 phenotype.
    Kypreos KE, Li X, van Dijk KW, Havekes LM, Zannis VI.
    Biochemistry; 2003 Aug 26; 42(33):9841-53. PubMed ID: 12924933
    [Abstract] [Full Text] [Related]

  • 10. Familial dysbetalipoproteinemia in three patients with apoE 2*(Arg136-->Cys) gene variant.
    Vrablík M, Horínek A, Ceska R, Stulc T, Kvasnicka T.
    Physiol Res; 2003 Aug 26; 52(5):647-50. PubMed ID: 14535841
    [Abstract] [Full Text] [Related]

  • 11. Hyperlipidemia of ApoE2(Arg(158)-Cys) and ApoE3-Leiden transgenic mice is modulated predominantly by LDL receptor expression.
    van Dijk KW, van Vlijmen BJ, de Winther MP, van 't Hof B, van der Zee A, van der Boom H, Havekes LM, Hofker MH.
    Arterioscler Thromb Vasc Biol; 1999 Dec 26; 19(12):2945-51. PubMed ID: 10591674
    [Abstract] [Full Text] [Related]

  • 12. Apolipoprotein E2 (Arg-136-->Cys), a variant of apolipoprotein E associated with late-onset dominance of type III hyperlipoproteinaemia.
    Feussner G, Albanese M, Mann WA, Valencia A, Schuster H.
    Eur J Clin Invest; 1996 Jan 26; 26(1):13-23. PubMed ID: 8682150
    [Abstract] [Full Text] [Related]

  • 13. Apolipoprotein E2(Arg158----Cys) frequency in a hyperlipidemic French-Canadian population of apolipoprotein E2/2 subjects. Determination by synthetic oligonucleotide probes.
    Weisgraber KH, Newhouse YM, Taylor JM, Tuan B, Nestruck AC, Davignon J, Mahley RW.
    Arteriosclerosis; 1989 Jan 26; 9(1):50-7. PubMed ID: 2912421
    [Abstract] [Full Text] [Related]

  • 14. Severe type III hyperlipoproteinemia associated with unusual apolipoprotein E1 phenotype and epsilon 1/'null' genotype.
    Feussner G, Funke H, Weng W, Assmann G, Lackner KJ, Ziegler R.
    Eur J Clin Invest; 1992 Sep 26; 22(9):599-608. PubMed ID: 1360898
    [Abstract] [Full Text] [Related]

  • 15. Triglyceride-rich lipoproteins of subjects heterozygous for apolipoprotein E2(Lys146-->Gln) are inefficiently converted to cholesterol-rich lipoproteins.
    Mulder M, van der Boom H, de Knijff P, Braam C, van den Maagdenberg A, Leuven JA, Havekes LM.
    Atherosclerosis; 1994 Aug 26; 108(2):183-92. PubMed ID: 7980718
    [Abstract] [Full Text] [Related]

  • 16. Incomplete dominance of type III hyperlipoproteinemia is associated with the rare apolipoprotein E2 (Arg136-->Ser) variant in multigenerational pedigree studies.
    Pocovi M, Cenarro A, Civeira F, Myers RH, Casao E, Esteban M, Ordovas JM.
    Atherosclerosis; 1996 Apr 26; 122(1):33-46. PubMed ID: 8724110
    [Abstract] [Full Text] [Related]

  • 17. Reversal of hypercholesterolemia in apolipoprotein E2 and apolipoprotein E3-Leiden transgenic mice by adenovirus-mediated gene transfer of the VLDL receptor.
    van Dijk KW, van Vlijmen BJ, van der Zee A, van't Hof B, van der Boom H, Kobayashi K, Chan L, Havekes LM, Hofker MH.
    Arterioscler Thromb Vasc Biol; 1998 Jan 26; 18(1):7-12. PubMed ID: 9445249
    [Abstract] [Full Text] [Related]

  • 18. Compound heterozygote for both rare apolipoprotein E1 (Gly127-->Asp, Arg158-->Cys) and E3(Cys112-->Arg, Arg251-->Gly) alleles in a multigeneration pedigree with hyperlipoproteinaemia.
    Richard P, Beucler I, Pascual De Zulueta M, Biteau N, De Gennes JL, Iron A.
    Clin Sci (Lond); 1997 Jul 26; 93(1):89-95. PubMed ID: 9279208
    [Abstract] [Full Text] [Related]

  • 19. Genetic factors precipitating type III hyperlipoproteinemia in hypolipidemic transgenic mice expressing human apolipoprotein E2.
    Huang Y, Rall SC, Mahley RW.
    Arterioscler Thromb Vasc Biol; 1997 Nov 26; 17(11):2817-24. PubMed ID: 9409260
    [Abstract] [Full Text] [Related]

  • 20. Type III dyslipoproteinemia in patients heterozygous for familial hypercholesterolemia and apolipoprotein E2. Evidence for a gene-gene interaction.
    Hopkins PN, Wu LL, Schumacher MC, Emi M, Hegele RM, Hunt SC, Lalouel JM, Williams RR.
    Arterioscler Thromb; 1991 Nov 26; 11(5):1137-46. PubMed ID: 1680391
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.